|
Poster number |
Title |
Submitting author |
City and Country |
|
127 |
Cladribine as frontline treatment of hairy cell leukemia: a multicenter European experience of more than 30 years on 384 patients |
Alessandro Broccoli |
Bologna, Italy |
|
128 |
MOLTO, a multicenter, open label, uncontrolled, phase II clinical trial on venetoclax, atezolizumab, obinutuzumab in Richter Transformation: safety interim analysis |
Anna Maria Frustaci |
Milan, Italy |
|
129 |
Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent BTK inhibitor in previously treated Richter transformation: Results from the phase 1/2 BRUIN study |
Wojciech Jurczak |
Krakow, Poland |
|
130 |
Preliminary results of the Phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib |
Mazyar Shadman |
Seattle, WA, USA |
|
131 |
Updated Efficacy and Safety Results of Orelabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia |
Wei Xu |
Nanjing, China |
|
132 |
Safety and Effectiveness of Venetoclax Monotherapy in Elderly Patients with Relapsed/Refractory CLL Under Real-Life Conditions – Data From the Observational Study VeRVe |
Ingo Schwaner |
Berlin, Germany |
|
133 |
Ibrutinib tolerability and outcome in patients with high-risk chronic lymphocytic leukemia |
Adalgisa Condoluci |
Bellinzona, Switzerland |
|
134 |
EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL-LIFE CAMPUS CLL STUDY |
Andrea Visentin |
Padova, Italy |
|
135 |
Ibrutinib followed by Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial from the Spanish Group of CLL (GELLC) |
Pau Abrisqueta |
Barcelona, Spain |
|
136 |
First-Line Treatment With Ibrutinib for Patients With Chronic Lymphocytic Leukemia (CLL): 7-Year Results From RESONATE-2 |
Steven Coutre |
Stanford, CA, USA |
|
137 |
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study |
Othman Al-Sawaf |
Cologne, Germany |
|
138 |
Unfavorable genetics impact MRD response to venetoclax+rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): Phase 3 MURANO substudy |
John Seymour |
Melbourne, Australia |
|
139 |
A Continuous Individualized Risk Index for refined outcome prediction after targeted therapy for patients with chronic lymphocytic leukemia (CIRI-CLL) |
Othman Al-Sawaf |
Cologne, Germany |
|
140 |
A Cross-sectional Study on the Global Differences in Information Experiences and Needs of Patients with Lymphoma and CLL |
Lorna Warwick |
Mississauga, Canada |
|
141 |
Impact of disease treatment on the outcome of patients with Chronic Lymphocytic Leukemia (CLL) with COVID-19: a multicenter study on behalf of GELLC |
Ana Muntañola |
Barcelona, Spain |
|
142 |
Dissecting the genetics of different anatomical compartments of small lymphocytic lymphoma with a multiregional sequencing apporach. |
Riccardo Moia |
Novara, Italy |
|
143 |
Kinase-dead Bruton’s tyrosine kinase (BTK) C481F/Y mutants confer ibrutinib resistance through activation of hematopoietic cell kinase (HCK) |
Kamaldeep Dhami |
Sunnyvale, CA, USA |